Amarin (AMRN)
(Delayed Data from NSDQ)
$0.64 USD
+0.01 (1.35%)
Updated Aug 26, 2024 04:00 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Amarin (AMRN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$1.00 | $1.00 | $1.00 | 56.25% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Amarin comes to $1.00. The forecasts range from a low of $1.00 to a high of $1.00. The average price target represents an increase of 56.25% from the last closing price of $0.64.
Analyst Price Targets (2 )
Broker Rating
Amarin currently has an average brokerage recommendation (ABR) of 4.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 3.50 a month ago based on four recommendations.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 4.33 | 4.33 | 3.50 | 3.50 | 3.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/1/2024 | SVB Securities | Roanna Ruiz | Hold | Hold |
3/31/2024 | Goldman Sachs | Paul K Choi | Strong Sell | Strong Sell |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 4.33 |
ABR (Last week) | 4.33 |
# of Recs in ABR | 3 |
Average Target Price | $1.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 253 |
Current Quarter EPS Est: | -0.05 |